ART signs GE
GE Medical Systems has agreed to distribute a preclinical optical molecular imaging system made by Advanced Research Technologies. The deal grants GE exclusive worldwide rights to distribute the system, called SAMITM, which is designed for use in the R&D
GE Medical Systems has agreed to distribute a preclinical optical molecular imaging system made by Advanced Research Technologies. The deal grants GE exclusive worldwide rights to distribute the system, called SAMITM, which is designed for use in the R&D of therapeutic and diagnostic drugs. The system is an optical fluorescence molecular imaging device designed to help pharmaceutical companies and research laboratories better understand disease and shorten the development cycle for new drugs. The technology is based on ART's proprietary time domain optical imaging technology, which noninvasively images tissue to reveal the biological distribution and concentration of fluorescence-labeled markers. GE holds an equity stake in the firm and is advising staff there on the development of clinical products based on the optical technology (SCAN 11/6/02).
The Reading Room Podcast: Current Perspectives on the Updated Appropriate Use Criteria for Brain PET
March 18th 2025In a new podcast, Satoshi Minoshima, M.D., Ph.D., and James Williams, Ph.D., share their insights on the recently updated appropriate use criteria for amyloid PET and tau PET in patients with mild cognitive impairment.
Study with CT Data Suggests Women with PE Have More Than Triple the One-Year Mortality Rate than Men
April 3rd 2025After a multivariable assessment including age and comorbidities, women with pulmonary embolism (PE) had a 48 percent higher risk of one-year mortality than men with PE, according to a new study involving over 33,000 patients.
